Milnacipran
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Milnacipran: From Fibromyalgia to Migraine Disorder
One-Sentence Summary
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed in the US as Savella. Published literature describes it as indicated for fibromyalgia. The TxGNN model predicts it may be effective for migraine disorder. Support is limited: 2 small clinical trials (one placebo-controlled, one open-label) and 1 open-label prospective study, with no efficacy results in the data provided.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fibromyalgia (taken from the literature; the license records contain no indication text) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 5 license records, all under NDA022256 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data from DrugBank is not available. Milnacipran is an SNRI, and it enhances serotonergic and noradrenergic signaling in descending pain-modulating pathways. Other SNRIs and antidepressants are used in migraine prevention, so the same mechanism plausibly applies here.
The link between the original and new indication is chronic pain modulation. Fibromyalgia is a central pain-sensitization condition, and migraine also involves altered pain processing and serotonergic signaling. One prospective study began from an observation in clinical practice: physicians noticed that patients with migraine who took milnacipran for fibromyalgia had fewer headaches.
The mechanistic argument is plausible but untested. Neither trial has reported efficacy results in the data provided, so the prediction is best treated as a research question.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01393522 | NA (not labeled) | Completed | 37 | Randomized, double-blind, placebo-controlled trial of twice-daily milnacipran for migraine pain. It is the most direct evidence, but no results were provided. |
| NCT01319825 | Phase 4 | Unknown | 45 | Open-label pilot of milnacipran for preventing episodic and chronic migraine. It is uncontrolled and its status is unknown, so it is hypothesis-generating only. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24030685 | 2014 | Prospective open-label cohort | Neurological Sciences | The most relevant paper. A 3-month pilot study in 45 patients (38 episodic, 7 chronic migraine) who kept headache diaries to assess milnacipran for headache prevention. Outcome figures are not in the excerpt provided. |
| 26798881 | 2015 | Review | Journal of the California Dental Association | A review of drug treatments for chronic orofacial pain. It says the fibromyalgia drugs (pregabalin, duloxetine, milnacipran) are “not robust”. It does not test milnacipran in migraine. |
| 21377931 | 2011 | Review | Current Opinion in Pharmacology | An opinion piece on 5-HT receptor ligands for pain (excluding IBS and migraine). It mentions SNRIs only as modulators of pain. Indirect relevance. |
| 31804357 | 2019 | Case report | Medicine | A case of reversible cerebral vasoconstriction syndrome, a condition that can be confused with migraine. It provides no evidence for milnacipran in migraine. |
| 22967190 | 2012 | Pharmacovigilance database analysis | Drug Safety | A methods paper on competition bias in safety-signal detection using French spontaneous reports. It provides no efficacy evidence. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA022256 | Savella | Film-coated tablet (oral) | Indication text not included in the data provided |
The 5 license records all fall under this NDA. Four are from Allergan, Inc. and one is from Cardinal Health 107, LLC.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: A small placebo-controlled trial and an open-label pilot exist for migraine, but no efficacy results were available to assess. Package-insert safety data is also missing, which blocks safety screening. The other nine TxGNN predictions (for example migraine with brainstem aura, tendinitis, and several myopathies) have no clinical evidence and should also stay on Hold.
To proceed, the following is needed:
- Results of NCT01393522 (the placebo-controlled migraine trial) and the full outcomes of the open-label study (PMID 24030685)
- The current package insert (warnings, contraindications, drug interactions) for safety screening
- Detailed mechanism-of-action data from DrugBank
- The approved indication text from the US label
- A comparison with established migraine preventives, including SNRI/antidepressant options, and a dosing and cardiovascular safety review for this population
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.